[Articles] Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised co

Upadacitinib 15 mg daily provides clinically meaningful repigmentation of both the face and total body for adults and adolescents with non-segmental vitiligo, with no new safety signals identified.

Medical Literature · Updated 2026-08-17

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.